http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1805513-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d73f701061bbc9c7c795aa825f4523 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2005-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87727d1be5e139d13d664517be7287a6 |
| publicationDate | 2007-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1805513-A2 |
| titleOfInvention | Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer |
| abstract | Macrophage migration inhibitory factor (MIF) has been found to be overexpressed in blood of individuals having various cancers, including prostate, PIN, lung, breast, ovary, kidney and bladder. Normal levels of MIF in serum of males and females without these cancers have been quantified via immunoassay. MIF can be used as a diagnostic tool either by itself or as an adjunct to or in combination with to conventional diagnostic tests. |
| priorityDate | 2004-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.